Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study.
Takehiro FunamizuHiroshi IwataYuya NishidaKatsutoshi MiyosawaShinichiro DoiYuichi ChikataJun ShitaraHirohisa EndoHideki WadaRyo NaitoManabu OgitaTomotaka DohiTakatoshi KasaiShinya OkazakiKikuo IsodaKatsumi MiyauchiHiroyuki DaidaPublished in: Cardiovascular diabetology (2020)
The findings indicate an increased risk of CV mortality by strict glycemic control (HbA1c < 6.5%) in the secondary prevention of CV disease in Japanese patients with medically-treated diabetes. Trial registration This study reports the retrospective analysis of a prospective registry database of patients who underwent PCI at Juntendo University Hospital, Tokyo, Japan (Juntendo Physicians' Alliance for Clinical Trials, J-PACT), which is publicly registered (University Medical Information Network Japan-Clinical Trials Registry UMIN-CTR 000035587).
Keyphrases
- glycemic control
- clinical trial
- type diabetes
- percutaneous coronary intervention
- blood glucose
- newly diagnosed
- weight loss
- coronary artery disease
- phase ii
- acute coronary syndrome
- cardiovascular events
- insulin resistance
- acute myocardial infarction
- st segment elevation myocardial infarction
- primary care
- st elevation myocardial infarction
- phase iii
- antiplatelet therapy
- ejection fraction
- healthcare
- coronary artery bypass grafting
- risk factors
- open label
- cardiovascular disease
- atrial fibrillation
- heart failure
- emergency department
- cross sectional
- metabolic syndrome
- double blind
- social media
- adipose tissue